Patents by Inventor Jonathan L. Blank

Jonathan L. Blank has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers of response to NAE inhibitors
    Patent number: 10953013
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 23, 2021
    Assignees: Millennium Pharmaceuticals, Inc., The General Hospital Corporation
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Lightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • BIOMARKERS OF RESPONSE TO NAE INHIBITORS
    Publication number: 20170105995
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: June 3, 2016
    Publication date: April 20, 2017
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Lightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • BIOMARKERS OF RESPONSE TO NAE INHIBITORS
    Publication number: 20150119410
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: October 26, 2012
    Publication date: April 30, 2015
    Applicants: Millennium Pharmaceuticals, Inc, Massachusetts General Hospital
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Llightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman